August 22, 2016
(The Baltimore Sun) – McGlothlin was part of a group study on the effects of psilocybin, the active hallucinogenic ingredient in “magic mushrooms,” on smoking cessation. The study represents a resurgence in research at Johns Hopkins, New York University and other academic institutions looking at whether mind-altering psychedelics, such as LSD, mushrooms and ecstasy can be effective in treating a variety of emotional and addictive disorders. Scientists have discovered that psychedelic drugs have the potential to relieve clinical depression, anxiety in cancer patients, depression in hospice patients, post-traumatic stress disorder and obsessive-compulsive disorder.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.